Banque Pictet & Cie’s TG Therapeutics TGTX Stock Holding History

Banque Pictet & Cie’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,915	Closed	-$296K	–	461
2025 Q4	$296K	Sell	9,915 -2,331	-19%	-$76.1K	﹤0.01%	359
2025 Q3	$442K	Sell	12,246 -78	-0.6%	-$2.57K	﹤0.01%	325
2025 Q2	$444K	Sell	12,324 -827	-6%	-$30.8K	﹤0.01%	300
2025 Q1	$519K	Buy	+13,151	New	+$442K	﹤0.01%	295

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Banque Pictet & Cie's TGTX Position: Q1 2026 in Review

Banque Pictet & Cie sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 9,915 shares — an estimated $296K sold.

Banque Pictet & Cie first reported a position in TGTX in Q1 2025 and held it in 4 quarters. The position peaked at $519K in Q1 2025. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Banque Pictet & Cie reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Banque Pictet & Cie sold 9,915 TG Therapeutics shares in Q1 2026, an estimated $296K.
Banque Pictet & Cie first reported a position in TG Therapeutics in Q1 2025 and held it in 4 quarters.
Banque Pictet & Cie's TG Therapeutics position peaked at $519K in Q1 2025.
365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Banque Pictet & Cie's 13F filing for Q1 2026, filed 14 Apr 2026.